No Data
No Data
Optimistic Outlook for Applied Therapeutics Despite FDA Setback
Applied Therapeutics Faces FDA Challenges With Govorestat
Express News | Applied Therapeutics: Following Issuance of a Complete Response Letter by FDA, Received Warning Letter Limited to at-007-1002 Study
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Express News | Applied Therapeutics Inc : UBS Cuts Target Price to $2 From $13
No Data
No Data